Single or combined immune checkpoint inhibitors compared to first-line chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer
Ferrara R., Imbimbo M., Paget-Bailly S., Malouf R., Calais F., Agazzi GM., Marchal C., Westeel V.
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: Primary To determine the efficacy and safety of first-line immune checkpoint inhibitors, or immuno-oncology therapy (IO), as monotherapy or in combination for patients with advanced non-small cell lung cancer (NSCLC). Secondary To maintain the currency of evidence by taking a living systematic review approach.